Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder - PubMed (original) (raw)
Clinical Trial
Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder
L J Van Oudheusden et al. Prostaglandins Leukot Essent Fatty Acids. 2002 Jul.
Abstract
To determine safety and the efficacy of carnitine treatment in children with attention-deficit hyperactivity disorder (ADHD). The ADHD behavior was observed by parents completing the Child Behavior Checklist (CBCL) and by teachers completing the Conners teacher-rating score, in a randomized, double-blind, placebo-controlled double-crossover trial. In 13/24 boys receiving carnitine, home behavior improved as assessed with the CBCL total score (P < 0.02). In 13/24 boys, school behavior improved as assessed with the Conners teacher-rating score (P < 0.05). Before treatment, the CBCL total and sub-scores were significantly different from those of normal Dutch boys (P < 0.0001). Responders showed a significant improvement of the CBCL total scores compared to baseline (P < 0.0001). In the majority of boys no side effects were seen. At baseline and after carnitine treatment, responders showed higher levels of plasma-free carnitine (P < 0.03) and acetylcarnitine (P < 0.05). Compared to baseline, the carnitine treatment caused in the responsive patients a decrease of 20-65% (8-48 points) as assessed by the CBCL total problem rating scale. Treatment with carnitine significantly decreased the attention problems and aggressive behavior in boys with ADHD.
Copyright 2002 Elsevier Science Ltd.
Similar articles
- A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys.
Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E, Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D'Iddio S, Calvani M, Neri G. Torrioli MG, et al. Am J Med Genet A. 2008 Apr 1;146A(7):803-12. doi: 10.1002/ajmg.a.32268. Am J Med Genet A. 2008. PMID: 18286595 Clinical Trial. - Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
Crippa A, Tesei A, Sangiorgio F, Salandi A, Trabattoni S, Grazioli S, Agostoni C, Molteni M, Nobile M. Crippa A, et al. Eur Child Adolesc Psychiatry. 2019 Apr;28(4):571-583. doi: 10.1007/s00787-018-1223-z. Epub 2018 Sep 24. Eur Child Adolesc Psychiatry. 2019. PMID: 30246216 Clinical Trial. - Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial.
Arnold LE, Amato A, Bozzolo H, Hollway J, Cook A, Ramadan Y, Crowl L, Zhang D, Thompson S, Testa G, Kliewer V, Wigal T, McBurnett K, Manos M. Arnold LE, et al. J Child Adolesc Psychopharmacol. 2007 Dec;17(6):791-802. doi: 10.1089/cap.2007.018. J Child Adolesc Psychopharmacol. 2007. PMID: 18315451 Clinical Trial. - Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L. Biederman J, et al. Pediatrics. 2005 Dec;116(6):e777-84. doi: 10.1542/peds.2005-0617. Pediatrics. 2005. PMID: 16322134 Clinical Trial. - Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
Akhondzadeh S, Mohammadi MR, Khademi M. Akhondzadeh S, et al. BMC Psychiatry. 2004 Apr 8;4:9. doi: 10.1186/1471-244X-4-9. BMC Psychiatry. 2004. PMID: 15070418 Free PMC article. Clinical Trial.
Cited by
- L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder.
Nie LJ, Liang J, Shan F, Wang BS, Mu YY, Zhou XH, Xia QR. Nie LJ, et al. Front Psychiatry. 2021 Sep 30;12:671151. doi: 10.3389/fpsyt.2021.671151. eCollection 2021. Front Psychiatry. 2021. PMID: 34658942 Free PMC article. - Emerging pharmacologic treatment options for fragile X syndrome.
Schaefer TL, Davenport MH, Erickson CA. Schaefer TL, et al. Appl Clin Genet. 2015 Apr 7;8:75-93. doi: 10.2147/TACG.S35673. eCollection 2015. Appl Clin Genet. 2015. PMID: 25897255 Free PMC article. Review. - Effect of a vitamin/mineral supplement on children and adults with autism.
Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, Gehn E, Loresto M, Mitchell J, Atwood S, Barnhouse S, Lee W. Adams JB, et al. BMC Pediatr. 2011 Dec 12;11:111. doi: 10.1186/1471-2431-11-111. BMC Pediatr. 2011. PMID: 22151477 Free PMC article. Clinical Trial. - Attention deficit/hyperactivity disorder as an associated feature in OCTN2 deficiency with novel deletion (p.T440-Y449).
Lamhonwah AM, Barić I, Lamhonwah J, Grubić M, Tein I. Lamhonwah AM, et al. Clin Case Rep. 2018 Feb 9;6(4):585-591. doi: 10.1002/ccr3.1316. eCollection 2018 Apr. Clin Case Rep. 2018. PMID: 29636919 Free PMC article. - Dietary and nutritional treatments for attention-deficit/hyperactivity disorder: current research support and recommendations for practitioners.
Hurt EA, Arnold LE, Lofthouse N. Hurt EA, et al. Curr Psychiatry Rep. 2011 Oct;13(5):323-32. doi: 10.1007/s11920-011-0217-z. Curr Psychiatry Rep. 2011. PMID: 21779824 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical